GT Medical Technologies, Inc. today announced it is presenting clinical data in two oral presentations on the company’s breakthrough GammaTile® Therapy for patients with brain tumors at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting.
This press release announces a trial collaboration between Novocure and GT Medical Technologies to develop Tumor Treating Fields (TTFields) together with GammaTile Therapy for the treatment of recurrent GBMs. Tumor Treating Fields are electric fields that disrupt cancer cell division. The study will evaluate the effectiveness and safety of adjuvantly using TTFields prior to resection + GammaTile, with progression free survival (PFS) for the ITT population being the primary endpoint.
GT Medical Technologies announces it has been honored by AZ Big Media with a 2021 Healthcare Leadership Award in the Healthcare Innovators of the Year category, which recognizes the best and the brightest in healthcare in Arizona.
An AdventHealth neurosurgeon and radiation oncologist became the first team in Central Florida to use a new and potentially life-extending technology called GammaTile during brain surgery for cancer patients.
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors.
Illustrating the expanded use of its innovative GammaTile® Therapy treatment for newly diagnosed malignant and recurrent brain tumors across the U.S., GT Medical Technologies Inc. today announced its 2020 roster of ELITE Distinguished Brain Tumor Specialists that have completed 10 or more GammaTile Therapy procedures in 2020.
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced it has raised $16 million in a Series B financing led by MVM Partners with participation from existing investors MedTech Venture Partners and BlueStone Venture Partners.
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors.
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced new data from a clinical study of the company’s GammaTile® Therapy in patients with large brain metastases
The Piedmont Brain Tumor Center is one of the first centers in the country to offer a leading-edge treatment for patients with newly diagnosed malignant and recurrent brain tumors.